A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Treatment of Elderly Patients with Generalised Anxiety Disorder (CHROMIUM Study).

Registry ID

EUCTR2006-001195-21

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

AstraZeneca AB

Start date

2006-08-01

Completion date

2008-05-22

Last update

2026-08-16

Conditions

• Generalised Anxiety Disorder

Summary

The primary objective of the study is to evaluate the efficacy of quetiapine fumarate sustained release (hereafter referred to as quetiapine SR) versus placebo in the treatment of anxiety symptoms in patients with Generalised Anxiety Disorder (GAD), as assessed by the change from randomisation in the HAM A total score at Day 64.

Locations

• , , Estonia

Related clinical trials

• Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders
• CBT and the Neural Circuits of Anxiety
• A Neuro-Technological Intervention for Adolescents With GAD

View on source registry